Week in Review: Roche to introduce MDx system at AMP2022; Thermo Fisher Scientific to acquire The Binding Site; LabCorp, Hologic, Bio-rad Laboratories report quarterly financial results

Leo Photo

Dear LabPulse reader,

With the Association for Molecular Pathology 2022 annual meeting and expo this week in Phoenix, we expect news about new products and studies from diagnostic testing vendors exhibiting at the event.

Roche on Tuesday has already generated headlines by saying it will showcase its Cobas 5800 System, a compact, fully automated molecular laboratory instrument, at the meeting.

The firm anticipates launching the system in U.S. markets in the fourth quarter. It has obtained U.S. Food and Drug Administration (FDA) premarket approval for its Cobas HIV-1 assay running on the 5800.

Recall that at AACC 2022 this past July, Roche competitor Siemens Healthineers unveiled the Atellica CI 1900 Analyzer. Unlike the Cobas 5800 molecular diagnostic system, the Siemens Healthineers product is a clinical chemistry and immunoassay testing system and lower-volume version of its on-the-market Atellica clinical chemistry and immunoassay testing solution.

AMP is also a venue for firms presenting data about product performance, and Biocartis announced that it will present nine study abstracts, including data on the performance of its fully automated molecular diagnostic Idylla platform and assays.

Look out for ongoing coverage of the event from LabPulse. For example, we have scheduled an interview with Thermo Fisher Scientific Chief Medical Officer Manoj Gandhi.

We last caught up with Manoj Gandhi during a video interview at AACC 2022 when he discussed ongoing shifts in the diagnostic testing landscape.

To address demand for specialty diagnostic assays and instruments to improve the diagnosis and management of blood cancers and immune system disorders, Thermo Fisher this week announced that it has signed an agreement to acquire The Binding Site Group in an all-cash transaction valued at 2.25 billion euros or $2.6 billion at current exchange rates.

Best wishes,

Leo O’Connor

Editor in Chief


Page 1 of 4
Next Page